JnJ enters innovative rheumatoid arthritis alliance
This article was originally published in Scrip
Executive Summary
UK biotech Modern Biosciences (MBS) has entered into an R&D alliance and global option and license agreement with J&J's Janssen Biotech for its novel bone-protective compounds for the treatment of rheumatoid arthritis. Under the deal, facilitated by the Johnson & Johnson Innovation Centre in London, MBS will receive an upfront payment and potential milestones of up to £176m and royalties on any future sales of products arising from the alliance.